

REMARKS

Upon entry of this Preliminary Amendment, original claims 1-25 have been cancelled. Claims 26-30 are pending. A priority information sentence has been added to the first line of the specification. An Abstract on a separate sheet is attached as required under 37 CFR 1.72(b).

Entry of this amendment into the record is requested.

Respectfully submitted,



Wayne J. Dustman
Attorney for Applicants
Registration No. 33,870

GLAXOSMITHKLINE
Corporate Intellectual Property-UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone: (610) 270-5023
Facsimile: (610) 270-5090
n:\wjd\paroxetine\p31178D7-C1preamend.doc

ABSTRACT OF THE DISCLOSURE

Invented is paroxetine hydrochloride anhydrate in Form B and paroxetine hydrochloride anhydrate in Form D. Also invented are pharmaceutical formulations comprising these compounds and methods of using these compounds in therapy.